reg, look at the latest post by Ex. He posted the link for the CI's 2017 output with a flat tail that continued to 2019 yielding a 50% OS in a combo situation. EX laments on the CI's hyper progression issue yet and didn't like the chemo part that kills good and bad cells both. What I am seeing is critics like Ex are accepting the power of immunotherapy that guarantees flat tail and good fat OS/PFS. With no hyperprogression and by going bthe nature's way, of course DCVax will dominate the immunotherapy world pretty soon. More than us BPs are watching us and no wonder MRK deployed Duffy with us. The Info Arm and the Blended JTM paper gave us real data that competes with Checkpoint Inhibitors and the projection by the k-m curves to OS4yr is a reality now when unblinded. And we will see DcVaxL k-m curve projected to 5,6, 7+ yrs and some in our L trial might live past 7+ yrs who knows. Unbelievable times are ahead for us! Cheers!!
News 
Market Data 
Discover 
